The use of centrifugated autologous lipoaspirate in the endoscopic management of idiopathic subglottic stenosis: results from a retrospective non-randomized study.
Mattioli F., Basso M., Moretti A., Morselli G., Vaccari C., Serafini E.
Retrospective Study with a reported sample of 19, published in Eur Arch Otorhinolaryngol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Eur Arch Otorhinolaryngol (2026)
- Country
- Germany
- Reported sample size
- 19
- Source database
- PubMed
- PMID
- 42228111
- DOI
- 10.1007/s00405-026-10322-9
Abstract (original English)
Purpose Idiopathic subglottic stenosis (iSGS) is a rare, progressive fibroinflammatory disease that predominantly affects middle-aged women. Although endoscopic treatments have improved, recurrence rates remain high and no standardized therapeutic approach has been defined. This exploratory retrospective pilot study aimed to assess feasibility, safety and explore the preliminary signal of benefit of intralesional injection of centrifuged autologous lipoaspirate as an adjunct to endoscopic balloon dilation in patients with iSGS. Methods A retrospective pilot observational study was conducted at the Tracheal Team of the University Hospital of M. and the Otorhinolaryngology Unit of S.O. Hospital, B., I., from 2015 to 2024. Twenty-six adult women with histologically confirmed iSGS and at least 12 months of follow-up were included. Patients received either standard endoscopic balloon dilation with intralesional corticosteroid injection (n=19) or balloon dilation followed by injection of centrifuged autologous lipoaspirate (n=7). The primary outcome was recurrence within 24 months, defined as the need for reintervention due to symptomatic restenosis. Secondary outcomes included time-to-recurrence, Subglottic Stenosis-6 (SGS-6) scores, and perioperative complications. Results Overall, recurrence occurred in 16 of 26 patients (61.6%). Recurrence was lower in the lipoaspirate group (2/7
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.